首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到19条相似文献,搜索用时 78 毫秒
1.
采用比较分子力场分析(CoMFA)和比较分子相似因子分析(CoMSIA)方法,对训练集中的26个楝酰胺(Rocaglamide)类化合物进行了三维定量构效关系(3D-QSAR)研究,最终建立的CoMFA模型和CoMSlA模型的q<'2>分别为0.593和0.656.并对测试集中的5个化合物的生物活性进行了预测,结果表明...  相似文献   

2.
利用中间体衍生化方法, 将噻吩环引入到双酰胺类化合物中, 合成了一系列取代噻吩双酰胺类化合物1~3; 目标化合物的结构经核磁共振波谱、 红外光谱及元素分析确认. 生物活性测试结果表明, 化合物1在600 mg/L剂量下对小菜蛾具有良好的杀虫效果, 致死率均为100%, 其中化合物1a和1e在20 mg/L剂量下对小菜蛾的致死率仍达到60%以上; 改变双酰胺结构中的吡唑环得到化合物2和3, 其杀虫活性消失, 说明该类化合物中吡唑环结构对杀虫活性具有关键作用.  相似文献   

3.
印楝素的合成、结构修饰及生物活性研究进展   总被引:8,自引:0,他引:8  
自印楝素被分离鉴定以来, 其广谱而独特的生物活性受到人们的广泛关注, 已成为一种近乎完美的植物源杀虫剂; 且在医药、保健、日化等领域都有广泛的应用.其复杂而独特的分子结构使得科研工作者进行了大量的全合成尝试、结构修饰及构效关系等研究. 综述了印楝素A的片段合成、全合成和印楝素有关的结构修饰以及生物活性等方面的研究进展.  相似文献   

4.
本文报道了一条简便合成烯酰胺类化合物的方法.在酸酐或酰氯的存在下,通过钛锌试剂还原硝基芳基乙烯类化合物一步生成芳基烯酰胺类化合物,并利用此法实现了天然产物Alatamide的合成.  相似文献   

5.
酰胺类化合物是有机化学中最常见的化合物之一, 在药物化学、生物化学以及高分子合成等领域都有着重要的应用. 近年来高效合成酰胺类化合物已经成为一个研究热点, 具有重要的意义.本文主要从过渡金属催化、有机小分子催化等方面讨论近几年来酰胺类化合物的合成研究进展, 并对其发展趋势进行展望.  相似文献   

6.
根据已知的激酶变构抑制剂与其靶点激酶的X射线共晶结构,设计了一系列以吡啶联异噁唑为中心结构的潜在激酶变构抑制剂.以2-甲基-5-硝基-3-吡啶甲酸甲酯为原料,通过形成酰胺、磺酰胺和连接嘧啶片段等衍生化手段合成了21个新的吡啶联异噁唑类化合物,其结构经1H NMR,13C NMR和MS确证.采用噻唑蓝(MTT)法测试了所合成化合物的体外抗肿瘤活性,初步测试结果表明该类化合物对肿瘤细胞的增长具有显著的抑制作用.  相似文献   

7.
α—取代乙酰胺类化合物结构与除草活性的构效关系研究   总被引:1,自引:0,他引:1  
分别研究了N,N-二取代-α-氯代乙酰胺类化合物及N,N-二取代-α-二硫代磷酰基之酰胺类化合物结构与除草活性的定量关系,结果表明,氮原子上取代基的大小对两类化合物的除草活性具有相同的影响,只是最适宜的疏水性不同,两类化合物可能具有相同的作用机制。  相似文献   

8.
天然化合物常表现出各种独特的生物活性,使其成为寻找和筛选各种生物活性物质如医药、农药等的天然宝库.楝酰胺(rocaglamide)(结构式如图式1)是从楝属植物中分离出的具有良好杀虫活性的化合物[1],对疆叶蛾的LC50为0.91μg/mL,与已知的天然杀虫剂苦楝素Azadirachtin(LC50为0.70μg/mL)的活性相当[2-4],这表明楝酰胺有可能成为一种极为重要的天然杀虫剂.  相似文献   

9.
在吡啶溶剂中,取代嘧啶胺与(取代)苯磺酰氯反应.合成了6个苯磺酰胺嘧啶类化合物(3a~3f),其结构经1H NMR和元素分析表征.初步的生物活性测试结果表明,3a~3f均具有一定的除草活性.  相似文献   

10.
苯酰胺类化合物是多巴胺D2受体的拮抗剂,它不仅与D2受体的亲和力高,而且产生的锥体外副反应极轻,是一类很有应用潜力的抗精神病药物.放射性同位素(123I等)标记的苯酰胺类化合物可作为多巴胺D2受体显像剂用于临床诊断疾病.近年来,相继报导了一系列高亲和力的该类化合物,其中,123IIBZM等已用于临床诊断疾病[1].本文在前文[2]苯酰胺类D2受体显像剂结构效应的研究基础上,利用SYBYL6.4软件,研究了该类化合物分子的不同构象以及空间结构与结合活性之间的关系,证实了前文提出的由于分子内氢键形成六元共平面假想A环、B环等是影响…  相似文献   

11.
Fast anionic oxy-Cope rearrangements of 1,5-hexadiyn-3,4-olates can be incorporated into cascade transformations which rapidly assemble densely functionalized cyclobutenes or cyclopentenones via a common bis-allenic intermediate. The competition between fragmentation, 4π-electrocyclic closure, and aldol condensation can be efficiently controlled by the nature of the acetylenic substituents. The rearrangement of bis-alkynes with two hydroxyl substituents opens a conceptually interesting entry in the chemistry of ε-dicarbonyl compounds and suggests a new approach to analogues of rocaglamide/aglafolin.  相似文献   

12.
A recently reported Pd0‐catalyzed asymmetric Nazarov‐type cyclization has been successfully applied in the key step of the first catalytic asymmetric total synthesis of (?)‐rocaglamide (natural) and (+)‐rocaglamide. The stereochemistry at the C3 position that controls the stereochemistry of all other stereocenters is determined in the cyclization step. This versatile and modular synthesis proceeds from simple reagents.  相似文献   

13.
The complex flavagline, (?)‐rocaglamide, possesses a synthetically intriguing tricyclic scaffold with five contiguous stereocenters and also exhibits potent anticancer, anti‐inflammatory and insecticidal activity. This full account details distinct approaches to (±)‐ and (?)‐rocaglamide utilizing Brønsted acid catalyzed and asymmetric Pd0‐catalyzed Nazarov chemistry developed in our laboratory, respectively. The successful asymmetric synthesis revealed unforeseen mechanistic complexity that required adjusting our strategy to overcome an unanticipated racemization process, an unusual reversible ring‐cleavage step and a very facile trialkylsilyl group migration.  相似文献   

14.
The synthesis of the key intermediate of rocaglamide, oxidative aglafolin, was studied, and its diastereoisomers were obtained. The amination of oxidative aglafolin was also investigated, affording amino derivatives. The preliminary bioassay results indicate that these new aglafolin derivatives showed certain degree of insecticidal and repellent activity against Plutella xylostella and Laphygma exigua.  相似文献   

15.
Enantioselective syntheses of methyl rocaglate and the related natural products rocaglamide and rocaglaol are outlined. The approach involves enantioselective [3 + 2] photocycloaddition promoted by chiral Br?nsted acids (TADDOLs) to afford an aglain precursor followed by a ketol shift/reduction sequence to the rocaglate core.  相似文献   

16.
Two new rocaglamide derivatives, 1-O-formylrocagloic acid (1) and 3'-hydroxy rocagloic acid (2), together with five known compounds, rocaglaol (3), rocagloic acid (4), 3'-hydroxymethylrocaglate (5), 1-O-formylmethyl rocaglate (6), and methylrocaglate (7), were isolated from the fruits of Amoora cucullata. Their structures were elucidated by spectroscopic methods. Compounds 1-3, 6, and 7 exhibited potent cytotoxicity against KB, BC, and NCI-H187 cell lines, whereas 4 and 5 showed selective cytotoxicity against NCI-H187 cell line.  相似文献   

17.
Chemical and biological properties of carzinophilin congeners obtained in the course of our synthetic studies were investigated. These studies revealed feasibility for the use of some analogues as a double alkylating agent. Further, analogues carrying the naphthalene and the epoxide parts were found to show remarkable in vitro cytotoxicity and in vivo antitumor activity.  相似文献   

18.
A series of pyrazole‐incorporated monocarbonyl analogues of curcumin were synthesized via Clasien–Schimidt‐type condensation and subsequently screened for in vitro antiproliferative and antioxidant activity. The analogues 4c, 5d, 5e, 5g, 6e, and 6f showed potential activity against the MDA‐MB‐231 cell line. The synthesized analogues were also screened for their antioxidant activity. Compounds 5a , 5e , 6d, and 6f exhibit comparable radical scavenging activity with respect to the standard drug ascorbic acid. Furthermore, a molecular docking study has been conducted for 5d and 5g and suggests that these compounds have a potential to become lead molecules in drug discovery and process.  相似文献   

19.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号